SINTEF, department of Biotechnology and Nanomedicine

Antisense RNA is broadly distributed in the CNS and exhibits a relatively long biological half-life. Following target identification by collaborators, Francis Combes designs and investigates novel treatments for CNS disorders such as Parkinson’s disease (Nilsen), glioblastoma (Pandey), and ischaemia (Rinholm) using gapmer and splice modulating antisense oligonucleotides.

Our research focuses on developing innovative solutions that address relevant problems in the nucleic acid therapeutics space. This includes novel assays for high throughput mRNA quality control, optimization strategies for in vitro transcription, translational switches for tissue-specific mRNA therapeutics, and antisense oligonucleotides for disorders of the CNS.